CureVac AG

Belkins
The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

news image

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

news image

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More

MEDICAL

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

news image

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More

AIKIDO PHARMA EXECUTES ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING RESEARCH AGREEMENT WITH COGIA BIOTECH LTD

AIkido Pharma | May 06, 2020

news image

AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and dis...

Read More
news image

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More
news image

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More
news image

MEDICAL

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More
news image

AIKIDO PHARMA EXECUTES ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING RESEARCH AGREEMENT WITH COGIA BIOTECH LTD

AIkido Pharma | May 06, 2020

AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and dis...

Read More